In 2021, two clinical trials in Science found that FMT can promote the response in immunotherapy-refractory melanoma patients (45) and FMT from ICIs-responders combined with anti-PD-1 therapy can overcome resistance to PD-1 blockade in melanoma patients (46). This evidence concerns the gene PDCD1 and melanoma.